Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000672727 | SCV000797862 | likely pathogenic | Hyperinsulinemic hypoglycemia, familial, 1 | 2018-02-13 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV001816679 | SCV002065883 | likely pathogenic | not provided | 2021-10-07 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001816679 | SCV002249680 | likely pathogenic | not provided | 2023-06-23 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 15 of the ABCC8 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ABCC8 are known to be pathogenic (PMID: 20685672, 23345197). This variant is not present in population databases (gnomAD no frequency). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 556689). Disruption of this splice site has been observed in individual(s) with autosomal recessive focal hyperinsulinism (PMID: 14692646, 30386300). |
Baylor Genetics | RCV003465516 | SCV004205556 | pathogenic | Type 2 diabetes mellitus | 2021-12-20 | criteria provided, single submitter | clinical testing |